search
Back to results

Liver Cancer Disparities in American Indian and Alaska Native Persons

Primary Purpose

Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ultrasound or abbreviated MRI
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Hepatocellular Carcinoma

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Cirrhosis, any etiology, or chronic HBV infection
  • High risk of HCC
  • Age 18-75
  • Competent to provide informed consent

Exclusion Criteria:

  • Prior diagnosis of HCC
  • Current suspicion of HCC
  • Prior receipt of any organ transplantation
  • Participation in another HCC screening trial
  • CTP score >=10
  • MELD-Na score >20
  • GFR<30
  • Poor life expectancy (<5 years)
  • Contraindication to MRI
  • Inability to complete study visits
  • Currently pregnant

Sites / Locations

  • Cherokee Nation Health ServiceRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Ultrasound + AFP

aMRI + AFP

Arm Description

Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months

Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months

Outcomes

Primary Outcome Measures

Compliance with screening protocol
Compliance with conducting all three screening tests
Feasibility of screening protocol
Proportion of screening tests conducted that employed the appropriate screening protocol and used appropriate documentation of findings with the LI-RADS system

Secondary Outcome Measures

Full Information

First Posted
March 22, 2022
Last Updated
June 13, 2022
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI), Cherokee Nation Health Services, Alaska Native Tribal Health Consortium
search

1. Study Identification

Unique Protocol Identification Number
NCT05304234
Brief Title
Liver Cancer Disparities in American Indian and Alaska Native Persons
Official Title
Liver Cancer Disparities in American Indian and Alaska Native Persons
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI), Cherokee Nation Health Services, Alaska Native Tribal Health Consortium

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Detailed Description
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV. We will compare the aMRI vs. the US arm with respect to the following outcomes: Compliance/feasibility of conducting all three screening tests (0, 6 and 12 months) - Primary Outcome Proportion of screening tests conducted that employed the appropriate screening protocol and used appropriate documentation of findings with the LI-RADS system - Primary Outcome Proportion diagnosed with HCC and stage at diagnosis - Secondary Outcome

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B

7. Study Design

Primary Purpose
Screening
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
we are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ultrasound + AFP
Arm Type
Active Comparator
Arm Description
Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months
Arm Title
aMRI + AFP
Arm Type
Active Comparator
Arm Description
Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months
Intervention Type
Diagnostic Test
Intervention Name(s)
Ultrasound or abbreviated MRI
Intervention Description
Abdominal ultrasound or abbreviated MRI
Primary Outcome Measure Information:
Title
Compliance with screening protocol
Description
Compliance with conducting all three screening tests
Time Frame
12 months
Title
Feasibility of screening protocol
Description
Proportion of screening tests conducted that employed the appropriate screening protocol and used appropriate documentation of findings with the LI-RADS system
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cirrhosis, any etiology, or chronic HBV infection High risk of HCC Age 18-75 Competent to provide informed consent Exclusion Criteria: Prior diagnosis of HCC Current suspicion of HCC Prior receipt of any organ transplantation Participation in another HCC screening trial CTP score >=10 MELD-Na score >20 GFR<30 Poor life expectancy (<5 years) Contraindication to MRI Inability to complete study visits Currently pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer R Harry
Phone
206-616-0397
Email
jharry@medicine.washington.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Stephanie Y Park
Phone
206-744-7050
Email
sypark22@uw.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George Ioannou, MD, MS
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cherokee Nation Health Service
City
Tahlequah
State/Province
Oklahoma
ZIP/Postal Code
74464
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorge Mera
First Name & Middle Initial & Last Name & Degree
Whitney Essex

12. IPD Sharing Statement

Learn more about this trial

Liver Cancer Disparities in American Indian and Alaska Native Persons

We'll reach out to this number within 24 hrs